Detecting disease early for tomorrow’s health
Company
Hummingbird’s Mission is to harness the power of blood bourne miRNAs to “read” the immune system’s response to disease, enhancing the potential for innovative disease screening, symptom-based diagnostics, disease-specific prognostics as well as monitoring of patient-centric therapies.
The privately held company is based in Heidelberg, Germany and Boston, USA.
Why we are doing what we are doing
Story
From a multicenter study to the development of a miRNA-based liquid biopsy diagnostics.
See Hummingbird's story!
1
Multicenter study
2
GOAL: FIND LINK BETWEEN DISEASES AND WHOLE BLOOD MIRNA
3
454 CLINICAL BLOOD SAMPLES 863 MIRNAS
4
CLINICALLY ROBUST PRE-ANALYTIC PROTOCOLS DEVELOPED
5
SPECIFIC MIRNA SIGNATURES IDENTIFIED IN MULTIPLE DISEASES
6
WHOLE BLOOD MIRNOME DISEASE DATABASE ESTABLISHED
7
RESULTS PUBLISHED IN NATURE METHODS, 2011
8
MIRNA-CANDIDATES FOR EARLY DIAGNOSIS & TREATMENT MONITORING DISCOVERED
9
IP SECURED UNMATCHED PATENT POSITION
10
VALIDATION STUDIES CONDUCTED
11
ON THE WAY TO A MIRNA-BASED DX TEST
Thinking different for tomorrow's health
People
Experienced leadership - motivated team - committed to delivering results
We are Hummingbird Diagnostics
Hummingbird's dedicated and experienced team is committed to delivering results. We will work with you from your first inquiry to the completion of your study to ensure that it is a success.
Our team has a proven track record in molecular diagnostics, genomic services, intellectual property, and bioinformatics.